
    
      CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells
      composed of ex vivo expanded allogeneic UCB cells.

      The trial ends when the last patient completes their last visit. The overall study objectives
      are to evaluate the safety and efficacy of CordIn™: single ex-vivo expanded cord blood unit
      transplantation in patients with hemoglobinopathies (sickle cell disease or thalassemia
      major) following a preparative therapy.
    
  